Display Settings:

Format
Sort by

Send to:

Choose Destination

Results: 5

1.

Is follow-up BRAF(V600E) mutation analysis helpful in the differential diagnosis of thyroid nodules with negative results on initial analysis?

Yoon JH, Kim EK, Moon HJ, Kwak JY.

PLoS One. 2013;8(3):e58592. doi: 10.1371/journal.pone.0058592. Epub 2013 Mar 7.

PMID:
23505540
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

BRAF mutation in papillary thyroid carcinoma.

Li X, Abdel-Mageed AB, Kandil E.

Int J Clin Exp Med. 2012;5(4):310-5. Epub 2012 Aug 22.

PMID:
22993650
[PubMed]
Free PMC Article
3.

The Akt inhibitor MK2206 synergizes, but perifosine antagonizes, the BRAF(V600E) inhibitor PLX4032 and the MEK1/2 inhibitor AZD6244 in the inhibition of thyroid cancer cells.

Liu R, Liu D, Xing M.

J Clin Endocrinol Metab. 2012 Feb;97(2):E173-82. doi: 10.1210/jc.2011-1054. Epub 2011 Nov 16.

PMID:
22090271
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

The B-Raf status of tumor cells may be a significant determinant of both antitumor and anti-angiogenic effects of pazopanib in xenograft tumor models.

Gril B, Palmieri D, Qian Y, Anwar T, Ileva L, Bernardo M, Choyke P, Liewehr DJ, Steinberg SM, Steeg PS.

PLoS One. 2011;6(10):e25625. doi: 10.1371/journal.pone.0025625. Epub 2011 Oct 5.

PMID:
21998674
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Hypoxia-inducible factor in thyroid carcinoma.

Burrows N, Babur M, Resch J, Williams KJ, Brabant G.

J Thyroid Res. 2011;2011:762905. doi: 10.4061/2011/762905. Epub 2011 Jun 16.

PMID:
21765994
[PubMed]
Free PMC Article

Display Settings:

Format
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk